Posts

Building a Profitable Urology PCD Territory: Matching Your Product Portfolio to What's Actually Being Prescribed

  Most guides to urology PCD franchises tell you the market is growing and monopoly rights are good business. Both true, but neither tells you the thing that actually determines whether your territory makes money in year one: whether your product portfolio matches what urologists, general physicians, and nephrologists in your specific area are actually prescribing. "Urology" isn't one market. It's four, and treating it as one is the most common mistake new franchise partners make. This breaks down the sub-segments inside urology, how to read your own territory before committing to a product mix, and what to ask a prospective franchisor so your portfolio actually fits the prescriptions being written around you. Why "Urology" Isn't One Market A urology product list on a franchise brochure usually blends four genuinely different therapeutic needs into one category. They don't share a prescriber base, a patient profile, or a reorder rhythm, and stocking ...
Post a Comment
Read more

The Future of Vonoprazan PCD Pharma Business in India: What the Next Few Years Actually Look Like

  Every so often, a single molecule reshapes an entire therapy category faster than anyone expects. In Indian gastroenterology, that molecule right now is Vonoprazan. Within a year of wider availability, Vonoprazan-based formulations became the best-selling new drug launch in the Indian Pharmaceutical Market, generating roughly ₹187 crore in sales across more than 400 brands, according to IQVIA's market feedback data. For anyone evaluating a Vonoprazan PCD pharma business in 2026, that's not a marginal trend — it's one of the clearest commercial signals the gastro segment has produced in years. This piece looks beyond the current hype cycle: why Vonoprazan is displacing older acid-control therapies, what the data actually says about where this market is headed through 2027 and beyond, and what a franchise partner should weigh before signing on with any Vonoprazan PCD company. Why Vonoprazan Is Displacing Traditional PPIs For over two decades, Proton Pump Inhibitors — panto...
Post a Comment
Read more

Vonoprazan HP Kit: Composition, Dosage Schedule & PCD Franchise Investment Guide (2026)

  Quick answer: The Vonoprazan HP Kit is a combination therapy for H. pylori eradication that packages Vonoprazan (a potassium-competitive acid blocker) with amoxicillin — and often clarithromycin for triple therapy — plus Domperidone, taken as a coordinated 7-to-14-day course. For a PCD franchise partner, it's structured as a standard monopoly-basis product: a valid drug license, GST registration, and a signed franchise agreement are all that's required to onboard, with first-order values typically in the ₹30,000–₹50,000 range and profit margins around 20–40%, consistent with most monopoly PCD gastro lines. What differs from a standalone tablet product is that pricing, minimum order quantities, and supply reliability are all tied to the full three-component kit rather than a single molecule. The rest of this guide breaks down what's actually in the kit, why it's dosed the way it is, who it's not suited for, and what a franchise partner should specifically check be...
Post a Comment
Read more

The Janus Pharma Insights: Listen to Our Latest Pharma Podcast Episodes

Image
The Janus Pharma Insights is a podcast focused on pharmaceutical innovation, skincare manufacturing, emerging therapies, and business opportunities in the Indian healthcare sector. Through expert discussions and industry insights, we cover topics ranging from third-party manufacturing and PCD pharma franchises to new treatment options and market trends.  Janus Pharma Insights - Podcast by Janus Biotech Our podcast is available across major streaming platforms, including Spotify, Apple Podcasts, Amazon Music, iHeartRadio, Castbox, Podcast Addict, Podchaser, and Spreaker. Explore our latest episodes below and listen on your favorite platform. Episode 1: The Rise of Niacinamide Serum Manufacturing in India This episode explores the increasing demand for niacinamide serum manufacturing in India, private-label skincare production, and the growing opportunities in the cosmetics and pharmaceutical industries. Listen here: Spreaker: https://www.spreaker.com/episode/the-rise-of-niacinamide...
Post a Comment
Read more